Sivelestat
- Generic Name
- Sivelestat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N2O7S
- CAS Number
- 127373-66-4
- Unique Ingredient Identifier
- DWI62G0P59
- Background
Sivelestat has been used in trials studying the treatment of Acute Lung Injury and Respiratory Distress Syndrome, Adult.
- Indication
用于治疗伴有全身炎症反应综合征的急性肺损伤（ALI）和急性呼吸窘迫综合征（ARDS）。
- Associated Conditions
- -
- Associated Therapies
- -
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 2000
- Registration Number
- NCT06381661
Efficacy and Safety of Sivelestat in Preventing Postoperative Acute Respiratory Distress Syndrome After Cardiac Surgery :a Single Centre Random Control Trial.
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-02-28
- Target Recruit Count
- 384
- Registration Number
- NCT06276569
Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Nanjing Medical University
- Target Recruit Count
- 500
- Registration Number
- NCT06195267
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Beijing, China
🇨🇳The First Affiliated Hospital of Nanjing Medical University and Jiang ye-fan, Nanjing, China
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury
Phase 1
Completed
- Conditions
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT00036062
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath